FindTrial
Sign In

Treatment of Recurrent Bladder Cancer With Dendritic Cells

Treatment of Recurrent Bladder Cancer With Autologous Monocyte-derived Dendritic Cells

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04184232
Enrollment
17
Registered
2019-12-03
Start date
2019-07-01
Completion date
2020-12-31
Last updated
2021-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

Bladder Cancer, Dendritic cells

Brief summary

Treatment of recurrent bladder cancer with dendritic cells

Interventions

BIOLOGICALDendritic cells

Autologous dendritic cells primed with muc-1/wt-1 peptides

OTHERStandard treatment according to the Clinical protocols

Standard treatment of bladder cancer according to the Clinical protocols

Sponsors

Belarusian State Medical University
CollaboratorOTHER
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed diagnosis of pTa bladder cancer; * Patient who require repetitive transurethral resection; * Expression of muc-1/wt-1 by the tumor; * EGOC 0-3;

Exclusion criteria

* any medical condition which can be associated with the high risk for the patient; * pregnancy/lactation; * chronic infections, including hepatitis B/C, tuberculosis, HIV

Design outcomes

Primary

MeasureTime frameDescription
Efficacy evaluation1 year1 year relapse free survival

Countries

Belarus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026